Clinical trials: Rivaroxaban
Atrial Fibrillation
Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation
The primary purpose of this study is to evaluate the effectiveness of an intervention with a mobile adherence platform, compared to physician- or nurse-guided standard of care, to improve medication adherence to rivaroxaban in…
- Trial name
- NCT02996435
- Testing
- Mobile Application Intervention, No Intervention
- Where
- 25 sites in United States
- Volunteers
- 139 people
- Sponsor
- Janssen Scientific Affairs, LLC
Pulmonary Embolism
Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China
EINSTEIN PE study demonstrated that rivaroxaban is at least as effective as the current standard therapy with 51% relative risk reduction of major bleeding (1.1% vs.
- Trial name
- XAPEC (NCT03410706)
- Testing
- Rivaroxaban(Xarelto, BAY 59-7939)
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Bayer
Atrial Fibrillation, Intracerebral Hemorrhage
NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH
To determine the feasibility of a controlled trial examining the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) compared with ASA for stroke prevention in patients with a high-risk of atrial…
- Trial name
- NASPAF-ICH (NCT02998905)
- Testing
- NOAC, Acetylsalicylic Acid
- Where
- 9 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Population Health Research Institute
Oral Anticoagulant, Atrial Fibrillation
Laboratory Assessment of the Concentration of Direct Oral Anticoagulants in Patients With Atrial Fibrillation
The incidence of thromboembolic and bleeding event associated with catheter ablation for atrial fibrillation(CAAF) varies from 0.9% to 5% during peri-operative period.
- Conditions
- Oral Anticoagulant, Atrial Fibrillation, Pharmacokinetics and Pharmacodynamics
- Trial name
- LOAF (NCT04684056)
- Volunteers
- 1,864 people
- Sponsor
- Wuhan Asia Heart Hospital
Ventricular Tachycardia, Premature Ventricular Contraction
DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
The purpose of this study is to learn if taking a drug called direct oral anticoagulant after an ablation procedure keeps blood clots from forming and lowers the chance of having a stroke in patients with ventricular tachycardia…
- Conditions
- Ventricular Tachycardia, Premature Ventricular Contraction, Stroke
- Trial name
- STROKE-VT (NCT02666742)
- Testing
- DOAC, Aspirin
- Where
- 5 sites in United States, India
- Volunteers
- 246 people
- Sponsor
- Kansas City Heart Rhythm Institute
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)
This is a local, prospective, multicenter, non-interventional, observational study. Primary objective is to describe how in "real life" thromboprophylaxis is carried out after the discharge from a hospital in the patients who…
- Trial name
- SOPRANO (NCT01444586)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Russia
- Volunteers
- 2,293 people
- Sponsor
- Bayer
Nonvalvular Atrial Fibrillation
The Adherence to Oral Anticoagulant in Chinese Patients With NVAF
Investigate the compliance of oral anticoagulants in Chinese NVAF patients and find out the causes, so as to provide basis for formulating effective measures to improve the compliance of oral anticoagulants.
- Trial name
- NVAF (NCT04942873)
- Testing
- adherence
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Transcatheter Aortic Valve Replacement
Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes
To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE).
- Trial name
- GALILEO (NCT02556203)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic Acid (ASA), Clopidogrel
- Where
- 140 sites in United States, Austria and 15 more
- Volunteers
- 1,653 people
- Sponsor
- Bayer
Ischemic Heart Disease, Atrial Fibrillation
Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients
Preliminary experiences suggest that intermittent anticoagulation guided by continuous electrocardiographic monitoring can reduce the incidence of bleeding in patients with episodes of atrial fibrillation.
- Trial name
- INTERMITTENT (NCT04151680)
- Testing
- Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban, Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Left Atrial Appendage Closure, Thrombosis
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
The objective of the study is to compare short-term (8 weeks) anticoagulation therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter LAAC.
- Conditions
- Left Atrial Appendage Closure, Thrombosis, Stroke, TIA
- Trial name
- ANDES (NCT03568890)
- Testing
- Rivaroxaban, dabigatran, apixaban, or edoxaban, Clopidogrel -75 mg/day, Low dose aspirin -80 to 125 mg/day-
- Where
- Canada
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Transcatheter Aortic Valve Replacement
Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)
The main objective of this study is to demonstrate that a single anticoagulant therapy is superior to a combination of anticoagulant and antiplatelet therapy on the net clinical benefit estimated at 12 months after a…
- Trial name
- AVATAR (NCT02735902)
- Testing
- Vitamin K antagonist or direct oral anticoagulant treatment, Aspirin
- Where
- 6 sites in France
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Intracardiac Thrombus
Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population
The goal of this observational study is to determine the efficacy of rivaroxaban treatment for intracardiac thrombi resolution in pediatric patients (< 16 years old) diagnosed with intracardiac thrombosis.
- Trial name
- NCT06371170
- Testing
- Rivaroxaban
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Azienda Ospedaliero, Universitaria Ospedali Riuniti
Coronary Artery Disease, Peripheral Arterial Disease
Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Conditions
- Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation
- Trial name
- NCT03718429
- Testing
- Rivaroxaban 2.5 mg Tablet
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- University of Florida
Sickle Cell Disease, Central Venous Catheter Thrombosis
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
Research Question: In adult SCD patients with CVC, is it feasible and safe to conduct an adequately powered RCT to evaluate the use of rivaroxaban as thromboprophylaxis in this population? Study Design: The study is a vanguard…
- Conditions
- Sickle Cell Disease, Central Venous Catheter Thrombosis, Venous Thromboembolism
- Trial name
- THIS (NCT05033314)
- Testing
- Rivaroxaban 10 MG
- Where
- 3 sites in Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Non-valvular Atrial Fibrillation
Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation
The efficacy and safety of a novel oral Xa inhibitor for stroke and systemic embolism, namely rivaroxaban, in non-valvular atrial fibrillation patients are evaluated in Japanese clinical practice.
- Trial name
- EXPAND (NCT02147444)
- Where
- Japan
- Volunteers
- 7,000 people
- Sponsor
- Tohoku University
Cardiovascular Disease, Coronary Artery Disease
Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention
Balloon angioplasty (Percutaneous Coronary Intervention (PCI)) is commonly used to treat patients with obstructive coronary artery disease (CAD).
- Trial name
- X-PLORER (NCT01442792)
- Testing
- UFH, Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban (Xarelto, BAY59-7939) and UFH
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 108 people
- Sponsor
- Bayer
Atrial Fibrillation, Ischemic Stroke
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)
The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) for stroke prevention in patients with non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Systemic Embolization, Major Bleed
- Trial name
- NCT03568916
- Testing
- Apixaban (ATC B01AF02), Dabigatran (ATC B01AE07), Rivaroxaban (ATC B01AF01)
- Where
- Canada
- Volunteers
- 227,579 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Atrial Fibrillation
Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation
Atrial fibrillation is common and increases the risk of clotting especially in patients with multiple clotting risk factors. Patients treated with warfarin, an oral anti-coagulant, require frequent lab monitoring and dose…
- Trial name
- NCT01578044
- Testing
- Intervention, Control
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Venous Thromboembolism
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (deep vein thrombosis) or PE (pulmonary embolism) who completed 6 or 12…
- Trial name
- NCT00439725
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 322 sites in United States, Australia and 31 more
- Volunteers
- 1,197 people
- Sponsor
- Bayer
Atrial Fibrillation, Renal Dysfunction
A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban
This study aims to evaluate the recommended once-daily dosing of edoxaban and rivaroxaban in patients with atrial fibrillation (AF) and renal dysfunction in South Korea and Taiwan.
- Trial name
- NCT07874555
- Testing
- Edoxaban, Rivaroxaban
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 8,265 people
- Sponsor
- Daiichi Sankyo